Healthcare Equipment and Supplies
Company Overview of Semprus BioSciences Corp.
Semprus BioSciences Corp., a biomedical company, focuses on providing complication-free medical devices. The company’s Semprus Sustain technology is a permanent non-leaching biomaterial modification to the device surface that prevents medical complications, such as infection, blood clots, improper healing, and cell overgrowth. It focuses on enabling permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheters with a single surface modification. Semprus BioSciences also focuses on developing new products to reduce microbial adhesion, deliver drugs, bind with agents in the bloodstream, or provide improved accuracy for diagnostics. The company was formerly kno...
One Kendall Square
Building 1400 West
Cambridge, MA 02139
Founded in 2006
Key Executives for Semprus BioSciences Corp.
Co-Founder and Chief Technology Officer
Vice President of Business Development
Vice President of Product Development
Compensation as of Fiscal Year 2014.
Semprus BioSciences Corp. Key Developments
Semprus BioSciences Corp. Presents at Boston Biotech BD Boston Conference, Mar-25-2014 11:00 AM
Mar 14 14
Semprus BioSciences Corp. Presents at Boston Biotech BD Boston Conference, Mar-25-2014 11:00 AM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: David L. Lucchino, Co-Founder, Chief Executive Officer and Director.
Semprus BioSciences Corp. Receives FDA 510(k) Clearance for Nylus PICC with Semprus Sustain Technology
Nov 14 12
Teleflex Incorporated has announced that Semprus BioSciences Corp. has been granted 510(k) clearance for the company's innovative vascular access catheter, the Nylus(TM) Peripherally Inserted Central Catheter (PICC) with Semprus Sustain(TM) Technology. The Nylus PICC is indicated to provide peripheral access to the central venous system for infusion, intravenous therapy, blood sampling, central venous pressure monitoring and power injection of contrast media. The FDA clearance follows the product's European market clearance in July, 2012. The Nylus PICC uses a long-lasting polymer surface modification designed to reduce the attachment of platelets and blood proteins at the surface of the medical device. This provides benefits to the patient, the caregiver and the health care system. The Nylus PICC has been shown to reduce platelet adhesion and thrombus accumulation by 99% in both in vitro and acute animal testing.
Semprus BioSciences Corp. Presents at The 14th Annual Southeast BIO (SEBIO) Investor Forum, Nov-01-2012 08:30 AM
Oct 9 12
Semprus BioSciences Corp. Presents at The 14th Annual Southeast BIO (SEBIO) Investor Forum, Nov-01-2012 08:30 AM. Venue: The Breakers Resort, Palm Beach, Florida, United States. Speakers: David L. Lucchino, Co-Founder, Chief Executive Officer and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|